“`html
Willow Biosciences Reports Results from Annual Shareholders Meeting
SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company”) WLLW CANSF has announced the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the “Meeting”). Approximately 59,214,893 common shares, representing about 40.88% of the Company’s issued and outstanding shares, were present at the meeting.
The shareholders approved the number of directors for Willow, set at 5. The following nominees were elected as directors for the upcoming year, along with their voting results:
|
Votes For |
Votes Withheld |
|||
|
Director |
# |
% |
# |
% |
|
Dr. Chris Savile |
46,902,346 |
88.3% |
6,234,676 |
11.7% |
|
Dr. Jim Lalonde |
46,965,380 |
88.4% |
6,171,642 |
11.6% |
|
Donald Archibald |
44,900,287 |
84.5% |
8,236,735 |
15.5% |
|
Raffi Asadorian |
[Insert Votes] |
[Insert %] |
[Insert Votes] |
[Insert %] |
“`
Willow Biosciences Reports Successful Voting Results from Annual Meeting
At the Annual General and Special Meeting held on April 25, 2025, shareholders of Willow Biosciences approved several key resolutions. Detailed voting results, including the total number of votes and percentages, are included below.
| Director | Votes For # | Votes For % | Votes Against # | Votes Against % |
|---|---|---|---|---|
| Al Foreman | 46,963,057 | 88.4% | 6,173,965 | 11.6% |
| 46,900,723 | 88.3% | 6,236,299 | 11.7% |
Shareholders voted on the following matters, all detailed in the Company’s management information circular dated March 26, 2025 (the “Information Circular“).
| Approval Item | Votes For # | Votes For % |
|---|---|---|
| Appointment of KPMG LLP as auditor | 51,882,364 | 87.6% |
| Sale of shares of Epimeron USA, Inc. | 46,996,397 | 88.4% |
| Authorization to amend Articles for name change | 48,853,362 | 82.5% |
For a comprehensive report on all approved voting results, refer to the Company’s Report of Voting Results issued on April 25, 2025, which is accessible on SEDAR+ at www.sedarplus.ca.
About Willow Biosciences Inc.
Willow develops and manufactures precision fermented functional ingredients for various sectors, including health and wellness, food and beverage, and personal care. The company’s FutureGrownTM biotechnology platform emphasizes sustainable large-scale production. Willow’s R&D team has a solid record in creating and marketing bio-based manufacturing processes and products that benefit B2B partners and their customers.
For more details, please contact:
Travis Doupe
Chief Financial Officer
Email: [email protected]
Source: Willow Biosciences Inc.
